These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1266 related articles for article (PubMed ID: 16785336)

  • 1. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction.
    Sørensen R; Abildstrom SZ; Torp-Pedersen C; Gislason GH
    J Cardiovasc Nurs; 2008; 23(1):14-9. PubMed ID: 18158501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
    Schjerning Olsen AM; Fosbøl EL; Lindhardsen J; Folke F; Charlot M; Selmer C; Lamberts M; Bjerring Olesen J; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
    Circulation; 2011 May; 123(20):2226-35. PubMed ID: 21555710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
    García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
    Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M; Rahme E; Richard H; Pilote L
    Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.
    Gislason GH; Rasmussen JN; Abildstrom SZ; Schramm TK; Hansen ML; Fosbøl EL; Sørensen R; Folke F; Buch P; Gadsbøll N; Rasmussen S; Poulsen HE; Køber L; Madsen M; Torp-Pedersen C
    Arch Intern Med; 2009 Jan; 169(2):141-9. PubMed ID: 19171810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.